Equity
€266,925 ▲ 13.4%
Ebosch has made a profit without a break since 2013.
Ebosch
Lifetime
20 annual accounts with figures on one time axis, 25 filings since 2001peak €118,222 (2024)
€111,425▼ 5.7%
lowest -€8,238 (2012)
€53,711▼ 17.1%
peak €266,925 (2025)
€266,925▲ 13.4%
€229,211▲ 10.2%
peak 1.1 FTE (2008)
-not published
Board2 names since 2005
2 directors and 1 other
Documentsfilings and deeds
24-07-20267 days before the deadline
2025micro format
Dividend €22,106Equity from €235,321 to €266,925Investments €64,360
Key points
from the 2025 annual accountsInvestments
€64,360 3.3 × depreciation
Green is investment, beige is depreciation.
Filings
25 annual accounts since 2001
The last five annual accounts were filed 1 to 32 days before the end of the period.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 20,135 companies had the same profile as Ebosch has now. Each dot stands for 51 companies, two years later.
95.0%
were still trading
4.7%
stopped another way
0.2%
went bankrupt
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 20,135 companies, not a prediction for Ebosch. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0467582263
Company renamed from DR.V.SCHIETTEKATTE&DR.D.EBO to EBOSCH
General meeting of 22-09-2022 · Gazette deed
Company renamed from Dr. V. Schiettekatte & Dr. D. Ebo to EBOSCH
Reappointments: (director) and (director) · General meeting of 22-09-2022 · Gazette deed
Registered office moved from Sint-Niklaas to Bazel
New registered office: Kemphoekstraat 48, 9150 Bazel · Previous registered office: Rietvelde 13-9100 Sint Niklaas · General meeting of 31-07-2019 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| Ebosch Beveren-Kruibeke-Zwijndrecht | €496,137 | €111,425 | 53.8% | - |
| DR. ROBERT HOFFBAUER EN DR. ANNA SILEGHEM Heusden-Zolder | €509,229 | €112,995 | 80.3% | - |
| BERGER ANNICK Jette | €499,099 | €116,067 | 92.1% | - |
| DR. ELS NOE Antwerp | €504,737 | €116,424 | 97.0% | - |
| DR. Paul Zegers Antwerp | €477,382 | €115,515 | 68.7% | - |
| CABINET DE DERMATOLOGIE DOCTEUR PAQUET Sprimont | €469,725 | €113,078 | 97.5% | - |
| DR. KATHLEEN DEPLA Kontich | €463,830 | €117,682 | 82.0% | - |
These companies have the same main activity as Ebosch: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €464,000 and €509,000, founded between 1998 and 2000.
Official details
Source: KBO- Status
- Active since 23-11-1999Normal situation
- Activity
- Specialist medical practiceNACE 86220
- Establishment unit
- 2.216.653.0079150 Beveren-Kruibeke-Zwijndrecht, since 18-11-1999
- Financial year end
- 31 December
- Peppol
- Reachable since 06-01-2026
Annual accounts 2025
- ≈ €210,000estimated
- €496,137▲ 11.9%
- Filing
- Filed on 24-07-2026, 7 days before the end of the filing period
Insights on Ebosch
Ebosch files the micro format. That format states no turnover. The gross margin rose from €111,243 in 2006 to €111,425 in 2025.
The balance sheet grew most from 2021 to 2023 through fixed assets.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about Ebosch
- What is the company number of Ebosch?
- The company number of Ebosch is 0467.582.263. The VAT number is the same number with BE in front: BE 0467.582.263.
- Where is Ebosch based?
- The registered office is at Kemphoekstraat 48, 9150 Beveren-Kruibeke-Zwijndrecht.Company details
- What does Ebosch do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of Ebosch?
- Ebosch is a private limited company (BV).
- When was Ebosch founded?
- Ebosch was founded on 23-11-1999.
- Is Ebosch still active?
- Yes, Ebosch is an active enterprise in the KBO register.
- What is the turnover of Ebosch?
- The turnover in financial year 2025 is ≈ €210,000. This figure is estimated from the gross margin of €111,425 and 40 comparable companies (NACE 86220). It probably lies between €180,000 and €280,000.Financials
- Is Ebosch profitable?
- In financial year 2025, Ebosch made a profit of €53,711.
- Where can I find the annual accounts of Ebosch?
- Ebosch filed 25 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Ebosch due?
- Ebosch must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.